Cipla Limited (NSE:CIPLA)
1,307.00
+70.70 (5.72%)
Apr 23, 2026, 3:30 PM IST
Cipla Revenue
Cipla had revenue of 69.63B INR in the quarter ending December 31, 2025, with 0.02% growth. This brings the company's revenue in the last twelve months to 279.67B, up 4.67% year-over-year. In the fiscal year ending March 31, 2025, Cipla had annual revenue of 272.67B with 6.78% growth.
Revenue (ttm)
279.67B
Revenue Growth
+4.67%
P/S Ratio
3.77
Revenue / Employee
9.23M
Employees
30,313
Market Cap
1.05T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 272.67B | 17.31B | 6.78% |
| Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
| Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
| Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
| Mar 31, 2021 | 191.21B | 20.40B | 11.94% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 331.82B |
| Zydus Lifesciences | 260.89B |
| Glenmark Pharmaceuticals | 165.10B |
| Alkem Laboratories | 142.53B |
| Mankind Pharma | 139.14B |
| Divi's Laboratories | 103.14B |
| Ipca Laboratories | 95.06B |
| Emcure Pharmaceuticals | 88.50B |
Cipla News
- 12 hours ago - Cipla gets USFDA nod for first AB-rated generic of Ventolin HFA - Business Upturn
- 12 hours ago - Cipla receives USFDA approval for first AB-rated generic of Ventolin HFA - Business Upturn
- 1 day ago - Pharma sector stocks today, April 22: Natco Pharma up 1.4%, Lupin falls 1.01%, Cipla down 0.73% - Business Upturn
- 6 days ago - Cipla receives two inspectional observations from USFDA at Goa facility - Business Upturn
- 10 days ago - Pharma sector stocks fall today, April 13: Biocon falls 2.35%, Cipla down 1.66%, Ajanta Pharma gains 0.77% - Business Upturn
- 20 days ago - Cipla Gets FDA Approval For Generic Nintedanib Capsules - Nasdaq
- 24 days ago - Cipla appoints new senior management personnel amid leadership changes - Business Upturn
- 27 days ago - Cipla, Bajaj Finserv & more: Top stocks to watch today - The Times of India